Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07278479 · ClinicalTrials.gov registry record · Phase 1

Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors

A Phase 1 study of Small Cell Lung Cancer (SCLC) and Large Cell Neuroendocrine Carcinoma, sponsored by Molecular Partners.

Recruiting
Registry status
Phase 1
Development phase
138
Enrollment target
1
Study location

NCT07278479 is a Phase 1 study of Small Cell Lung Cancer (SCLC) and Large Cell Neuroendocrine Carcinoma that is actively recruiting participants, run by Molecular Partners. The registered enrollment target is 138 participants, below the 349-participant average among 9 other Small Cell Lung Cancer (SCLC) trials with a reported enrollment target (60% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07278479, a Phase 1 study of Small Cell Lung Cancer (SCLC) and Large Cell Neuroendocrine Carcinoma, is actively recruiting participants, sponsored by Molecular Partners.

RECRUITING
Registry status
Phase 1
Development phase
138 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[212Pb\]Pb-MP0712, in patients aged ≥18 years with Small Cell Lung Cancer and other locally advanced or metastatic DLL3 positive tumors.

Conditions Studied

Small Cell Lung Cancer (SCLC) Large Cell Neuroendocrine Carcinoma Extrapulmonary Neuroendocrine Carcinoma (EP-NEC) Large Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC) Gastroenteropancreatic NEC (GEP NEC) NEC of the Bladder Other DLL3 Expressing epNEC

Interventions

  • DRUG [212Pb]Pb-MP0712
  • OTHER [203Pb]Pb-MP0712

Study Locations (1)

Nebraska

  • Nebraska Cancer Specialists - Omaha

Trial Details

FieldValue
Enrollment Target 138 participants
Start Date 2026-01
Est. Completion 2032-09
Phase Phase 1

Sponsor

Molecular Partners

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07278479

The ClinicalTrials.gov registry entry for NCT07278479 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 138 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 349-participant average among 9 other Small Cell Lung Cancer (SCLC) trials with a reported enrollment target (60% lower). The listed sponsor is Molecular Partners, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 7 conditions, with Small Cell Lung Cancer (SCLC) appearing as the primary indexed condition, and to 2 interventions - of which [212Pb]Pb-MP0712 is the first listed.

NCT07278479 reports 1 study location spanning 1 distinct geographic area - top geographies include Nebraska.

Frequently Asked Questions

What is clinical trial NCT07278479 about?

NCT07278479 is a clinical study titled "Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors". The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[212Pb\]Pb-MP0712, in patients aged ≥18 years with Small Cell Lung Cancer and other locally advanced or metastatic DLL3 positive tumors.

What is the current status of trial NCT07278479?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 138 participants. The study started on 2026-01. Estimated completion is 2032-09.

What conditions does trial NCT07278479 study?

This clinical trial studies the following conditions: Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Carcinoma, Extrapulmonary Neuroendocrine Carcinoma (EP-NEC), Large Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC), Gastroenteropancreatic NEC (GEP NEC).

What interventions are being tested in trial NCT07278479?

The interventions under investigation include: [212Pb]Pb-MP0712 (DRUG), [203Pb]Pb-MP0712 (OTHER).

Who is sponsoring clinical trial NCT07278479?

This trial is sponsored by Molecular Partners, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07278479 being conducted?

This trial has 1 study location across Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Small Cell Lung Cancer (SCLC)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Small Cell Lung Cancer (SCLC)

All registered trials for this condition

Large Cell Neuroendocrine Carcinoma

All registered trials for this condition

Nebraska

All trials with a study site in Nebraska

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.